$CNXU

Journey Medical (DERM) rose 13% on strong Q2 results, with revenue up 23% to $18.5M. Iovance (IOVA) gained 11% on 66% revenue growth to $99.3M. Caris (CAI) advanced 8% after raising 2026 revenue guidance to $1.03B-$1.04B. Prelude (PRLD) up 8% on narrower Q2 loss. Compugen (CGEN) gained 7% on COM701 trial progress. Conexeu (CNXU) rose 4% on regenerative aesthetics market opportunity.

Conexeu Sciences Inc. (CNXU) highlights a new category in medical aesthetics focused on tissue regeneration. Independent research estimates the bioregenerative-aesthetics market at $1.6B in 2025, growing 11% annually. Conexeu's CXU platform, an ECM-based collagen scaffold, has completed a 12-month preclinical study meeting objectives. The company aims to restore tissue structure rather than just replace volume.

Biotech Insider commentary highlights Conexeu Sciences (Nasdaq: CNXU), a preclinical company developing CXU and its Ten-Minute Tissue device that transitions from fluid to extracellular matrix gel in about 10 minutes. It plans a predicate-based 510(k) submission in early 2027. The piece also cites regenerative peers including Vericel (VCEL) with Q2 2026 revenue of $77.5M.

IPO Edge hosted a 30-minute fireside chat with Conexeu Sciences (Nasdaq: CNXU) CEO Miles Harrison. The preclinical regenerative tissue company discussed its ECM platform for wound care, aesthetics, oral health, and veterinary uses, including a bioresorbable scaffold for breast implants. It cited an anticipated FDA 510(k) submission in early 2027 and related catalysts.

Conexeu Sciences Inc. (NASDAQ: CNXU) says its investigational CXU tissue-restoration platform targets large-volume injectable aesthetics, aiming to restore body volume after GLP-1 weight loss. The company completed a 12-month P.R.O.O.F. preclinical study in a large-volume model, with results not yet peer-reviewed. Boston Consulting Group projects GLP-1-related aesthetic provider revenue could rise to about $2.0B by 2030.

Conexeu Sciences Inc. (Nasdaq: CNXU) says its preclinical CXU tissue-restoration platform targets large-volume body contouring needs created by GLP-1 weight loss. The company completed a 12-month P.R.O.O.F. preclinical study in small and large-volume models. Boston Consulting Group projects GLP-1-related aesthetic care revenue rising from about $0.7B to $2.0B by 2030.

Conexeu Sciences Inc. (Nasdaq: CNXU) says it has completed a 12-month preclinical P.R.O.O.F. study for its CXU tissue-restoration scaffold, aimed at large-volume injectable aesthetics. The company cites growing aesthetics markets and GLP-1-driven demand, and targets a 510(k) submission in Q1 2027, pending further testing.

Conexeu Sciences Inc. (NASDAQ: CNXU) says it completed its 12-month P.R.O.O.F preclinical phase for its CXU regenerative tissue platform, meeting objectives across facial, body, and mechanical performance pillars. The company plans a predicate-based 510(k) submission for its lead Ten-Minute Tissue device in Q1 2027, targeting faster review, subject to required testing and FDA review.

Conexeu Sciences (CNXU) said its 12-month P.R.O.O.F study for its CXU tissue-restoration platform met tissue restoration objectives in facial models and performance benchmarks for injectability and volumizing capacity. The company plans a predicate-based 510(k) wound-care path with a Q1 2027 submission and aims to use clearance to expand into medical aesthetics. Stock closed at $9.49.

Conexeu Sciences Inc. (NASDAQ: CNXU) says it completed the P.R.O.O.F preclinical phase of its CXU program, which it frames as an evidence base for a first move into medical aesthetics injectables. The company targets a predicate-based FDA 510(k) submission in Q1 2027. It cites a $11B aesthetics injectable market and GLP-1 growth projections.